[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367721-105":59,"doc-detail-367721-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oglcnacylation-as-an-emerging-molecular-target-for-cholangiocarcinoma-therapy-review","O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy - Review","","Aberrant O‑GlcNAcylation and increased O‑GlcNAc transferase (OGT) activity are presented as key drivers of cancer pathogenesis, promoting hyperproliferative behavior and metastatic phenotypes. The review argues that inhibiting OGT could restrain cancer progression and highlights OGT and O‑GlcNAc signaling as promising research targets. It focuses on cholangiocarcinoma, summarizing impacts on proliferation, metastasis, metabolic reprogramming, angiogenesis, programmed cell death, and inflammatory hallmarks, while discussing therapeutic feasibility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oglcnacylation-as-an-emerging-molecular-target-for-cholangiocarcinoma-therapy-review/367721/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oglcnacylation-as-an-emerging-molecular-target-for-cholangiocarcinoma-therapy-review/367721.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does O‑GlcNAcylation play in cancer according to the review?","Question",{"text":112,"@type":113},"Aberrant O‑GlcNAcylation and upregulated OGT are described as contributors to cancer pathogenesis and progression, supporting hyperproliferative and metastatic states.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is cholangiocarcinoma highlighted in this review?",{"text":117,"@type":113},"Cholangiocarcinoma is characterized as rare but highly aggressive, with rising mortality, poor survival, and high recurrence despite advances in awareness, diagnostics, and therapies.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review aim to cover regarding O‑GlcNAcylation in cholangiocarcinoma?",{"text":121,"@type":113},"It summarizes how O‑GlcNAcylation affects cholangiocarcinoma and related cancer hallmarks, including proliferation, metastasis, metabolic reprogramming, angiogenesis, programmed cell death, and tumor-associated inflammation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367721,1790526750,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","ONCOLOGY REPORTS 54: 119, 2025  \nO‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review)  \nPURIN CHAROENSUKSAI 1,2 and SIWANON JIRAWATNOTAI3‑5  \n1  \nDepartment of Biomedicine and Health Informatics, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand; 2  \nResearch and Innovation Center for Advanced Therapy Medicinal Products, Faculty of Pharmacy, Silpakorn University, 3  \nNakhon Pathom 73000, Thailand; Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of  \n4  \nMedicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; 5Faculty of Pharmacy, Silpakorn University, Nakhon Pathom 73000, Thailand  \nReceived April 22, 2025; Accepted June 19, 2025  \nDOI: 10. 3892/or.2025.8952  \nAbstract. Aberrant O‑GlcNAcylation and the upregula‑ tion of O‑GlcNAc transferase (OGT) are key contributors to cancer pathogenesis and progression, driving hyperp‑ roliferative states and metastatic phenotypes . Targeting OGT may suppress cancer progression, positioning OGT and O‑GlcNAc signaling as compelling targets in cancer research. Cholangiocarcinoma (CCA), a rare yet highly aggressive malignancy of the bile duct system, represents a clinical challenge, underscored by its rising global mortality, poor survival outcomes and high recurrence rate, despite advances in awareness, diagnostics and therapeutic strate‑ gies . Consequently, there is need for novel therapeutic modalities. Hyperactive O‑GlcNAcylation and upregulation of OGT are observed in CCA, therefore, targeting protein O‑GlcNAcylation may have clinical potential. The present review aimed to summarize the impact of O‑GlcNAcylationon CCA and CCA‑relevant hallmarks of cancer including cell proliferation, metastasis, metabolic reprogramming, angiogenesis, programmed cell death and tumor‑associated inflammation . In areas where direct evidence in CCA is limited, insights from other gastrointestinal tract cancers may identify potential mechanistic connections, offering abroader context to guide future investigation . Furthermore, the viability of OGT and O‑GlcNAcylation as therapeutic targets is discussed.  \nCorrespondence to: Dr Siwanon Jirawatnotai, Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, 12th Floor, Srisawarindhira Build, Bangkok 10700, Thailand  \nE‑mail: [siwanon.jir@mahidol.ac.th](siwanon.jir@mahidol.ac.th)  \nKey words: O‑GlcNAcylation, O‑GlcNAc transferase, cholangio‑ carcinoma, cancer precision medicine, O‑GlcNAcylation‑targeted therapy, sugar metabolism in cancer  \nContents  \n1. Introduction  \n2. Role of O‑GlcNAcylation for cancer development and progression: Implications for CCA  \n3. Conclusion  \n1. Introduction  \nO‑linked‑β‑N‑acetylglucosaminidation or O‑GlcNAcylationis a form of protein post‑translational modification involving the attachment of N‑Acetyl‑D‑glucosamine to serine or threo‑ nine residues of cell proteins (1) . The addition and removal of O‑GlcNAc moieties are the function of two key enzymes, O‑GlcNAc transferase (OGT) (2‑4) and O‑GlcNAcase (OGA) (5,6), respectively.  \nThe human OGT gene is located on the X chromosome at Xq13.1, near the centromere (Fig. 1A) (7) . This gene contains 23 exons and 21 introns, which undergo alternative splicing to produce three distinct protein isoforms, each differing primarily in its N‑terminal region: Nucleocytoplasmic OGT (ncOGT), mitochondrial OGT (mOGT) and shortform OGT (sOGT) . ncOGT, the longest isoform, consists of 1,046 amino acids and is derived from exons 1‑4 and 6‑23 (Fig. 1A and B) (8,9) . The second longest, mOGT, comprises 931 amino acids encoded by exons 5‑23. This isoform is uniquely characterized by a mitochondrial targeting sequence at its N‑terminus (10) . The shortest isoform, sOGT, contains 675 amino acids, derived from exons 10‑23 (8) .  \nThe crystal structure","cbCaiq46NToadsLw","https://ap.wps.com/l/cbCaiq46NToadsLw","pdf",6247025,21,"English","# 1. Introduction\n# 2. Role of O‑GlcNAcylation for cancer development and progression: Implications for CCA\n# 3. Conclusion","[{\"question\":\"What role does O‑GlcNAcylation play in cancer according to the review?\",\"answer\":\"Aberrant O‑GlcNAcylation and upregulated OGT are described as contributors to cancer pathogenesis and progression, supporting hyperproliferative and metastatic states.\"},{\"question\":\"Why is cholangiocarcinoma highlighted in this review?\",\"answer\":\"Cholangiocarcinoma is characterized as rare but highly aggressive, with rising mortality, poor survival, and high recurrence despite advances in awareness, diagnostics, and therapies.\"},{\"question\":\"What does the review aim to cover regarding O‑GlcNAcylation in cholangiocarcinoma?\",\"answer\":\"It summarizes how O‑GlcNAcylation affects cholangiocarcinoma and related cancer hallmarks, including proliferation, metastasis, metabolic reprogramming, angiogenesis, programmed cell death, and tumor-associated inflammation.\"}]","O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy - Review | PDF",1790172247,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4515e3dc6d32a06c8c8d27110a7f3d0.webp",983,1357,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58c3b3147fc4c4523d40be0f9ff9f3e2.webp",982,1356,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef809a01aefce2d5f066c1525b752373.webp",981,1354,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42079483772103eaee6db7fd78661711.webp",980,1353]